Trials / Completed
CompletedNCT01632358
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
A Randomized, Double-blind, Placebo Controlled, Crossover Study to Assess Safety and Tolerability, Pharmacokinetics, and Explore Pharmacodynamics of TAP311 in Patients With Mixed Dyslipidaemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 279 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAP311 capsules | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-07-02
- Last updated
- 2013-12-02
Locations
3 sites across 3 countries: United States, Jordan, Taiwan
Source: ClinicalTrials.gov record NCT01632358. Inclusion in this directory is not an endorsement.